The Filing Desk

USANA Health Sciences

USNA · NYSE · Consumer Staples · Financials, fiscal 2016 to 2025

USNA · Last close · November 13, 2026
$13.24
Value USANA Health Sciences yourself

USANA Health Sciences' revenue rose 8.3% to $925 million in fiscal 2025. Its operating margin was 4.0%, down from 7.8% a year earlier. Free cash flow was $9 million, down 83.3%. It paid out $28 million in dividends and buybacks, 323% of free cash flow. The diluted share count fell 3.1%.

USANA HEALTH SCIENCES, INC. Latest fiscal year ended January 3, 2026 10-K filed March 16, 2026 · 0000896264-26-000021 Updated
Revenue
$925M
8.3%
Operating margin
4.0%
3.7 pts
Net income
$11M
74.4%
Free cash flow
$9M
83.3%
Return on equity
2.0%
6.2 pts
Market cap
$245M
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What USANA Health Sciences does

USANA develops and makes nutritional supplements, functional foods and personal care products and sells them around the world. It was founded in 1992 and operates in 25 geographic markets. In 2025 it had $925 million in net sales and about 387,000 active customers in its core nutritional business.

It has historically sold through direct selling, in which independent Brand Partners sell its products and earn pay under a Compensation Plan. Mainland China is its largest market, at about 41.3% of net sales. It also sells in other ways: directly to consumers, through marketplaces such as Amazon, and through retailers.

In December 2024 it bought a majority interest in Hiya Health Products, which sells children's health and wellness products directly to consumers. In 2022 it bought Rise, a nutrition brand it has expanded.

Its biggest risks, as it describes them

  • Direct selling is closely watched and regulated, and changes in law or its enforcement could hurt its business.
  • Brand Partners breaking marketing or advertising laws, or promoting its Compensation Plan improperly.
  • Changes it must make to its Compensation Plan in some markets, or Brand Partners reacting badly to them.
  • Depending on Greater China for much of its business and expected growth, and the strict rules there.
  • A decline in sales or customers in China, or the government not approving its BabyCare business model.
From USANA Health Sciences's annual report on Form 10-K, filed March 16, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2016 to 2025, earnings per share fell 19.3% a year and net income 21.9% a year, while buybacks cut the share count by 26%.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments240288330182158
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage2,985.8x560.5x355.2x236.0x44.5x
Current ratio2.3x2.7x3.5x2.0x2.2x
Quick ratio1.7x2.2x3.0x1.5x1.4x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project USANA Health Sciences' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What USANA Health Sciences says to expect

  • Fiscal 2026: net sales and adjusted EBITDAWe are updating our fiscal 2026 outlook to consolidated net sales approaching $900 million and Adjusted EBITDA of $77 million.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 3, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought USANA Health Sciences shares on the open market, and 8 insiders sold $894,829.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Jun 16, 2026Brent NeidigChief Commercial OfficerSold5,002$19.45$97,289Form 4
Jun 15, 2026Brent NeidigChief Commercial OfficerSold909$20.01$18,189Form 4
Jun 12, 2026Brent NeidigChief Commercial OfficerSold1,602$20.15$32,280Form 4
Jun 8, 2026Paul A. JonesChief People OfficerSold5,561$18.50$102,878Form 4
Jun 1, 2026John Turman FlemingDirectorSold2,450$17.93$43,928Form 4
May 28, 2026Paul A. JonesChief People OfficerSold6,813$18.95$129,106Form 4
May 27, 2026Iiekking G DougChief Financial OfficerSold5,360$18.75$100,500Form 4
May 22, 2026Gilbert A FullerDirectorSold1,057$18.66$19,724Form 4
May 7, 2026Joshua FoukasChief Legal OfficerSold3,791$19.82$75,138Form 4
Mar 20, 2026Gilbert A FullerDirectorSold1,058$17.00$17,986Form 4
Mar 3, 2026Peter BenedictChief Information OfficerSold4,553$19.38$88,237Form 4
Feb 20, 2026Joshua FoukasChief Legal OfficerSold4,461$21.35$95,242Form 4
The latest 12 of 14 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−1.7%−1.3%9.2%
Altman Z''10.237.367.37
Accruals ratio−1.1%−2.8%−1.6%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positivePassPassPass
Cash from operations is positivePassPassPass
Return on assets roseFailFailFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio rosePassFailPass
Share count didn't riseFailPassPass
Gross margin rosePassPassFail
Revenue rose relative to assetsFailFailFail
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put USANA Health Sciences side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
USANA Health SciencesFY258.3%4.0%0.9%———
Nu SkinFY25−14.3%4.4%3.1%6.5%−0.1x7Compare
e.l.f. BeautyFY2624.6%4.5%11.6%3.8%3.6x4Compare
Nature's Sunshine ProductsFY255.7%5.2%6.0%23.6%−2.4x7Compare
The Honest CompanyFY25−1.9%−5.0%3.7%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue1,0061,0471,1891,0611,1351,186999921854925
Revenue growth9.5%4.1%13.6%−10.8%7.0%4.6%−15.8%−7.8%−7.2%8.3%
Gross profit826868988873926969805744693724
Research and development991010111112111211
Operating income139132188146176170108936637
Net income1006212610012511669644211
Diluted EPS (US$)3.992.535.124.415.865.733.593.302.190.58
Diluted shares (millions)25252523212019191919
Cash flow
Cash from operations137124152127160121104716122
Capital expenditure33131117151310141014
Free cash flow1041111411101451089456519
Dividends paid0000000000
Share buybacks6550105150571782512928
Acquisitions000000602030
Stock-based compensation16161516141413151514
Balance sheet at fiscal year end
Cash and short-term investments176247214235312240288330182158
Debt incl. finance leases——————————
Total assets471519554517641578596633748743
Total liabilities145156163165199183162136162157
Shareholders' equity325363391352442395434497532533
Margins and ratios
Gross margin82.1%82.9%83.1%82.3%81.6%81.6%80.6%80.8%81.1%78.3%
Operating margin13.8%12.7%15.8%13.8%15.6%14.3%10.8%10.1%7.8%4.0%
Net margin9.9%6.0%10.6%9.5%11.0%9.8%6.9%6.9%4.9%1.2%
Free cash flow margin10.4%10.6%11.8%10.4%12.8%9.1%9.4%6.1%6.0%0.9%
Rule of 40 (growth + FCF margin)19.9%14.7%25.4%−0.4%19.8%13.7%−6.5%−1.7%−1.3%9.2%
Return on capital——————————
Return on equity33.0%18.2%33.5%27.1%31.4%27.9%16.7%13.7%8.2%2.0%
Return on assets22.4%12.6%23.5%18.8%21.5%19.1%11.8%10.4%6.1%1.4%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: USANA Health Sciences' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with USANA Health Sciences.